AI assistant
Q32 Bio Inc. — Director's Dealing 2023
Jan 11, 2023
34891_dirs_2023-01-11_f433f1a3-8be2-43ee-a3df-3eaa2c10d580.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2023-01-09
Reporting Person: Blum Michael Lee (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-09 | Common Stock | S | 2454 | $1.3904 | Disposed | 13538 | Direct |
Footnotes
F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of restricted stock units.
F2: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.39 to $1.41. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 2.